Endometrial Genomic Profile in Endometrial Priming
Not Applicable
Completed
- Conditions
- Genomic Human Endometrial Expression Profile
- Interventions
- Procedure: endometrial biopsy
- Registration Number
- NCT01778452
- Lead Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Brief Summary
The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.
- Detailed Description
We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone
* 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 6
Inclusion Criteria
- 6 egg healthy volunteer egg donors.
- Volunteers.
- 18-35 years old
- Healthy.
- BMI <28.
Exclusion Criteria
-
- BMI > 28
- Smokers-
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Natural cycle endometrial biopsy Natural cycle endometrial biopsy, lh+7 Antagonist cycle + endometrial priming. endometrial biopsy Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5 Agonist cycle + endometrial priming. endometrial biopsy Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
- Primary Outcome Measures
Name Time Method genetic endometrial human profile expression Oocyte donors will be followed up for four to six months implantation related genes profile expression
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ivi Valencia
🇪🇸Valencia, Spain